Coherus Biosciences (CHRS) has shared an announcement.
Bryan McMichael, previously serving in key financial roles within the company since March 2021, has been appointed as the Chief Financial Officer of the company, effective August 1, 2024. McMichael, a Certified Public Accountant with a rich background in finance, including positions at Gilead Sciences, Inc. and NetApp, Inc., has no family ties or undisclosed transactions with the company’s directors or officers. Following his appointment, McMichael received a significant stock option award and a salary increase, along with a discretionary bonus threshold set at 50% of his base salary. He also signed an indemnification agreement with the company, a standard procedure that protects him against certain legal expenses.
See more insights into CHRS stock on TipRanks’ Stock Analysis page.
